The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index; 5 of the 6 sources its claims cite were checked for support.
State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
Open accessAbstract
Cases and costs of state-level opioid use disorder and fatal opioid overdose and per capita costs were calculated for each of the 38 states and the District of Columbia (DC) that met drug specificity requirements for mortality data in 2017. Combined costs of opioid use disorder and fatal opioid overdose varied substantially, ranging from $985 million in Wyoming to $72,583 million in Ohio. Per capita combined costs ranged from $1,204 in Hawaii to $7,247 in West Virginia.
Overview
CoChat Summary
TL;DR
CDC estimated state-level economic costs of opioid use disorder (OUD) and fatal opioid overdose for 2017 using national cost-per-case estimates applied to state case counts. Combined costs varied widely across the 38 states and DC studied, from $985 million in Wyoming to $72,583 million in Ohio, with the highest per capita costs concentrated in the Ohio Valley and New England.
Key findings
- The national 2017 economic cost was $1,021 billion: $471 billion for OUD and $550 billion for fatal opioid overdose.
- State combined costs ranged from $985 million in Wyoming to $72,583 million in Ohio; per capita combined costs ranged from $1,204 in Hawaii to $7,247 in West Virginia.
- High per capita combined costs were mainly in the Ohio Valley and New England; West Virginia, Ohio, and Kentucky ranked first, second, and fourth ($7,247, $6,226, and $5,491, respectively).
- Reduced quality of life was the largest OUD cost component, and value of statistical life lost was the largest fatal overdose component; together these accounted for approximately 84% of combined costs.
Methods
- CDC used national cost estimates to calculate state-level costs for OUD and fatal opioid overdose in 2017, limited to the 38 states and DC that met drug specificity requirements for mortality data.
- OUD case counts came from the National Survey on Drug Use and Health 2-Year Restricted-Use Data Analysis System (2016–2017); fatal opioid overdose counts and population estimates came from CDC’s WONDER database for 2017.
- State costs were calculated by multiplying national cost per case—$221,219 for OUD and $11.548 million for fatal opioid overdose—by state case counts; per capita costs divided combined state costs by state population.
Limitations
- The paper states four limitations: results are limited to 38 states and DC, so rankings do not apply to all 50 states; OUD cost was measured for a single year rather than lifetime; NSDUH likely underrepresents OUD prevalence because it excludes incarcerated and homeless persons; and national cost-per-case estimates were applied to states rather than calculating state-specific costs, which could bias estimates if state case characteristics differ from national ones.
- The text also makes evident that state cost differences are driven by applying uniform national unit costs to state case counts and populations, rather than by state-specific cost data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
5 Valid · 0 Not valid · 1 Not checked · 20 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cost per case of fatal opioid overdose ($11.548 million) was derived by dividing the total cost of fatal opioid overdose ($549,691 million) by the number of fatal opioid overdose cases (47,600) (3).”
What the sources say
- Supportedcites [3] Florence, 2021, The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017., Drug Alcohol Depend source
The Results report 47,600 fatal opioid overdoses in 2017 and total costs of $1,020.7 billion, including $471.0 billion attributable to opioid use disorder. The remainder is approximately $549.7 billion for fatal overdose; dividing it by 47,600 gives approximately $11.548 million per case. The copy reports rounded totals rather than the cited $549,691 million figure. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, previous reports have shown that these states had low per capita lifetime medical and work-loss costs from all fatal injuries (including opioid overdose) in 2014 (7).”
§ State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017 > Discussion
What the sources say
- Partly supportedcites [7] Luo, 2017, State-level lifetime medical and work-loss costs of fatal injuries—United States, 2014., MMWR Morb Mortal Wkly Rep sourceExperimental — accuracy not yet measured
The “Injuries from All Intents” table reports 2014 per-capita costs of $608 for Connecticut, $722 for Maine, and $550 for Massachusetts. The accompanying text identifies Massachusetts, but not Connecticut or Maine, among the five lowest-cost states. The Discussion says drug overdoses were included within unintentional fatal injuries, though their costs were not reported separately. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cost per case of opioid use disorder ($221,219) was derived by dividing the total U.S. cost of opioid use disorder ($470,975 million) during 2017 by the number of opioid use disorder cases the same year (2.129 million) (3).”
What the sources say
- Partly supportedcites [3] Florence, 2021, The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017., Drug Alcohol Depend sourceExperimental — accuracy not yet measured
The Results report approximately $471.0 billion in 2017 opioid use disorder costs and approximately 2.1 million people with the disorder, consistent with the claimed calculation in broad terms. Our copy does not give the more precise $470,975 million or 2.129 million figures, or state the resulting $221,219 cost per case. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cases and costs of state-level opioid use disorder and fatal opioid overdose and per capita costs were calculated for each of the 38 states and the District of Columbia (DC) that met drug specificity requirements for mortality data (4).”
- Also stated in: § State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017 · plain
“This report is limited to DC and the 38 states that met the requirement that at least one specific drug is named on the death certificate (4).”
What the sources say
- Supportedcites [4] Wilson, 2020, Drug and opioid-involved overdose deaths—United States, 2017–2018., MMWR Morb Mortal Wkly Rep source
The source paper’s methods state that its state-level analyses included 38 states and the District of Columbia with adequate drug specificity for 2017 and 2018. Its Discussion repeats that adequate drug-specificity data were available from only those jurisdictions. The citation supports the selection criterion, not the citing authors’ cost calculations. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Reduced quality of life was the largest component of the cost of opioid use disorder, and the value of statistical life lost was the largest component of the cost of fatal opioid overdose (Table 2).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
14 more claims
Create a free account to see all 26 claims and every source verdict.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
“2.0 million persons met the diagnostic criteria for an opioid use disorder in 2017”
§ State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
“the number of opioid use disorder cases the same year (2.129 million)”
Citations
Cites
Drug Overdose Deaths in the United States, 1999–2020
Hedegaard, H., Miniño, A., Spencer, M. R., & Warner, M. (2021) · doi:10.15620/cdc:112340 · Cited by 1,283
Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018
Wilson, N., Kariisa, M., Seth, P., Smith, H., & Davis, N. L. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6911a4 · Cited by 1,123
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013) · BMJ · doi:10.1136/bmj.f174 · Cited by 999
Medications for Opioid Use Disorder Save Lives
Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Division, H. A. M., & National Academies of Sciences, E. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 715
The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017
Florence, C., Luo, F., & Rice, K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108350 · Cited by 511
Self-citationDowell, D., Zhang, K., Noonan, R. K., & Hockenberry, J. M. (2016) · Health Affairs · doi:10.1377/hlthaff.2016.0448 · Cited by 264
State-level lifetime medical and work-loss costs of fatal injuries—United States, 2014.
Luo, F., & Florence, C. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6601a1 · Cited by 136
Self-citationNational Survey on Drug Use and Health: 8-Year R-DAS (2002 to 2009)
United States Department Of Health And Human Services. Substance Abuse And Mental Health Services Administration. Center For Behavioral Health Statistics And Quality (2012) · ICPSR Data Holdings · doi:10.3886/icpsr32101 · Cited by 24
Cited by
Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02252-2 · Cited by 421
Bruns, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 97
Rao, I. J., Humphreys, K. N., & Brandeau, M. L. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100031 · Cited by 84
Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review
Daksla, N., Wang, A. C., Jin, Z., Gupta, A., & Bergese, S. D. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s372612 · Cited by 61
Understanding stigma through the lived experiences of people with opioid use disorder
Judd, H., Yaugher, A. C., O’Shay, S., & Meier, C. L. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110873 · Cited by 50
Metadata
- Authors
- Luo, F., Li, M., & Florence, C.
- Affiliations
- National Center for Injury Prevention and Control (US)
- Corresponding author
- Luo, Feijun
- Venue
- MMWR Morbidity and Mortality Weekly Report
- Published
- 2021-04-16
- Volume
- 70
- Issue
- 15
- Pages
- 541-546
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- PMC
- PMC8344997
- OpenAlex
- W3153902266
- Cited by
- 166
- References
- 7
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 33 · 2023: 41 · 2022: 29 · 2021: 10
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- MMWR Morbidity and Mortality Weekly Report (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- opioid use disorder, economic costs, per capita cost, opioid epidemic, health care costs, drug overdose deaths, resource allocation
- MeSH terms
- Opiate Overdose, Humans, Opioid-Related Disorders, United States, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017. https://app.cochat.ai/papers/10.15585/mmwr.mm7015a1
- The paper
- Luo, F., Li, M., & Florence, C. (2021). State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7015a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.